AU2017227534A1 - Combination therapy for treatment of ovarian cancer - Google Patents

Combination therapy for treatment of ovarian cancer Download PDF

Info

Publication number
AU2017227534A1
AU2017227534A1 AU2017227534A AU2017227534A AU2017227534A1 AU 2017227534 A1 AU2017227534 A1 AU 2017227534A1 AU 2017227534 A AU2017227534 A AU 2017227534A AU 2017227534 A AU2017227534 A AU 2017227534A AU 2017227534 A1 AU2017227534 A1 AU 2017227534A1
Authority
AU
Australia
Prior art keywords
inhibitor
dna
repair
damaging
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017227534A
Other languages
English (en)
Inventor
David Proia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2017227534A1 publication Critical patent/AU2017227534A1/en
Priority to AU2023200554A priority Critical patent/AU2023200554A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017227534A 2016-02-29 2017-02-28 Combination therapy for treatment of ovarian cancer Abandoned AU2017227534A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023200554A AU2023200554A1 (en) 2016-02-29 2023-02-03 Combination therapy for treatment of ovarian cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301225P 2016-02-29 2016-02-29
US62/301,225 2016-02-29
PCT/US2017/019843 WO2017151554A1 (en) 2016-02-29 2017-02-28 Combination therapy for treatment of ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023200554A Division AU2023200554A1 (en) 2016-02-29 2023-02-03 Combination therapy for treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
AU2017227534A1 true AU2017227534A1 (en) 2018-08-30

Family

ID=59744380

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017227534A Abandoned AU2017227534A1 (en) 2016-02-29 2017-02-28 Combination therapy for treatment of ovarian cancer
AU2023200554A Abandoned AU2023200554A1 (en) 2016-02-29 2023-02-03 Combination therapy for treatment of ovarian cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023200554A Abandoned AU2023200554A1 (en) 2016-02-29 2023-02-03 Combination therapy for treatment of ovarian cancer

Country Status (9)

Country Link
US (1) US11154538B2 (cg-RX-API-DMAC7.html)
EP (1) EP3423048A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019508429A (cg-RX-API-DMAC7.html)
CN (1) CN108697666A (cg-RX-API-DMAC7.html)
AU (2) AU2017227534A1 (cg-RX-API-DMAC7.html)
CA (1) CA3014680A1 (cg-RX-API-DMAC7.html)
IL (1) IL261195B (cg-RX-API-DMAC7.html)
MX (1) MX2018010223A (cg-RX-API-DMAC7.html)
WO (1) WO2017151554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
KR20200106053A (ko) * 2017-12-29 2020-09-10 버텍스 파마슈티칼스 인코포레이티드 Atr 억제제를 사용한 암 치료 방법
JP2021510702A (ja) 2018-01-12 2021-04-30 プロリンクス エルエルシー 相乗的がん治療
EP3966782A2 (en) 2019-05-06 2022-03-16 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113462784B (zh) * 2021-08-31 2021-12-10 迈杰转化医学研究(苏州)有限公司 一种构建用于同源重组修复缺陷检测的靶标集合的方法
JPWO2023157891A1 (cg-RX-API-DMAC7.html) 2022-02-16 2023-08-24
WO2024111564A1 (ja) * 2022-11-21 2024-05-30 富士フイルム株式会社 トポテカン又はその塩を内包するリポソーム組成物およびdna損傷修復阻害剤を含む組合せ医薬
CN116024162B (zh) * 2023-02-27 2025-01-10 山东大学 Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用
TW202502354A (zh) * 2023-06-02 2025-01-16 美商薩諾管理公司 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症
CN117860753A (zh) * 2023-11-30 2024-04-12 华中科技大学 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
EP2714033A1 (en) * 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
WO2013067162A1 (en) * 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
JP6114075B2 (ja) * 2013-03-07 2017-04-12 三菱航空機株式会社 航空機の警報システム、及び、航空機
US20160120848A1 (en) * 2013-05-21 2016-05-05 Synta Pharmaceuticals Corp. Specific cancer treatment regimes with ganetespib
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens

Also Published As

Publication number Publication date
JP2024054312A (ja) 2024-04-16
MX2018010223A (es) 2018-11-09
US11154538B2 (en) 2021-10-26
CN108697666A (zh) 2018-10-23
CA3014680A1 (en) 2017-09-08
WO2017151554A1 (en) 2017-09-08
US20190060285A1 (en) 2019-02-28
AU2023200554A1 (en) 2023-03-02
IL261195B (en) 2022-06-01
JP2019508429A (ja) 2019-03-28
EP3423048A1 (en) 2019-01-09
JP2022079569A (ja) 2022-05-26
IL261195A (en) 2018-10-31
EP3423048A4 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
US11154538B2 (en) Combination therapy for treatment of ovarian cancer
Fu et al. BRCA1 and breast cancer: molecular mechanisms and therapeutic strategies
US20220175752A1 (en) Methods of Treating Ovarian Cancer
US10851425B2 (en) Method for treating cancer
Begg et al. Strategies to improve radiotherapy with targeted drugs
Lee et al. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Xu et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients
US11028448B2 (en) Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension
Tufail DNA repair pathways in breast cancer: from mechanisms to clinical applications
Wu et al. Studies of lncRNAs in DNA double strand break repair: what is new?
US20180209956A1 (en) HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies
Chatterjee et al. Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer
WO2021011609A1 (en) Methods of treating ovarian, fallopian tube and peritoneal cancer
WO2011085288A2 (en) Method of administration and treatment
Yoon et al. Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer
Tyszka et al. Niraparib maintenance in newly diagnosed advanced ovarian cancer—review and case series
EP4686475A1 (en) Xpg inhibitors for use in the treatment of cancer
Jackson The DNA Damage Checkpoint
CA3036568C (en) Methods for treating ovarian cancer
Treré et al. Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis
WO2025109076A1 (en) Biomarkers for identifying patients having tumors with homologous recombination deficiency
TW202131925A (zh) 治療癌症之方法
Chau Landscape of Molecular Alterations of Three Rare Subtypes of Non-small Cell Lung Cancer
WO2024243078A1 (en) Hsp90 inhibitors for the treatment of cancer
TW202610631A (zh) 用於以2,2'-二硫基雙乙烷磺化物、卡鉑及吡咯葉酸治療非小細胞肺癌的方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted